Fig. 3: Sensitivity of patient isolates to SARS-CoV-2 specific monoclonal antibodies.
From: SARS-CoV-2 infection dynamics in a MHCI-mismatched lung transplant recipient
3D representations of (a) the Omicron BA.1 variant receptor-binding domain (RBD) in complex with the fab fragment of sotrovimab (pdb accession 7X1M:) or (b) the S RBD in complex with the fabs of cilgavimab and tixagevimab (pdb accession: 7L7E). The mutational sites at position R346, K356, L368 and T385 are highlighted in red. c–e Neutralizing capacity of the therapeutic antibodies (c) sotrovimab, (d) cilgavimab and (e) tixagevimab. Serial 10-fold dilutions of the monoclonal antibodies were incubated with 100 pfu of the prototypic wildtype Omicron B.1 variant, a prototypic Omicron BA.2 variant or the two patient Omicron BA.2 isolates (d81 and d141) and analyzed by plaque assay. Neutralization titers 50 (NT50) values were calculated from individual curve fits of each serial dilution (3 biologically independent experiments). Shown are the mean and standard deviation. Statistics were performed on log-transformed values with a one-way ANOVA (Tukey’s multiple comparison test, **p ≤ 0.01, ***p ≤ 0.001).
